Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects
Antonio García-Gómez(Institut d'Investigació Biomédica de Bellvitge), Mercedes Garayoa(Universidad de Salamanca)
Cited by 78
Related Papers
Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease
|Nature Communications|2021|54